Metformin Use in Gestational Diabetes

Primary Treatment Recommendation

The American Diabetes Association recommends insulin as the preferred and recommended first-line agent for treating gestational diabetes mellitus (GDM) when lifestyle modifications fail to achieve glycemic control 1, 2, 3, 4
Metformin and glyburide are not recommended as first-line treatment because they cross the placenta and long-term safety data for offspring raises concerns 1, 2, 3

Metformin can be used as an alternative in women with GDM who cannot use insulin safely or effectively due to cost, language barriers, comprehension issues, or cultural factors 2, 3
Women with GDM who are considered for metformin must receive thorough counseling about known risks and the lack of long-term offspring safety data 2, 3, 4

Treatment failure rates are substantial, with 14-46% of women initially treated with metformin requiring supplemental insulin to achieve adequate glycemic control 1
Approximately 25-28% of women with GDM fail to achieve adequate control with metformin monotherapy 2, 3

Metformin readily crosses the placenta, resulting in umbilical cord blood levels equal to or higher than maternal levels 5
The MiG TOFU study found that 9-year-old children exposed to metformin in utero were heavier with higher waist-to-height ratios and waist circumferences compared to insulin-exposed children 5
Follow-up studies at 4-10 years showed offspring exposed to metformin had higher BMI, weight-to-height ratios, waist circumferences, and borderline increased fat mass 1, 2, 3
Meta-analyses demonstrate metformin exposure results in smaller neonates with acceleration of postnatal growth leading to higher BMI in childhood 1, 2, 3

The American Diabetes Association recommends initiating lifestyle modifications for all women with GDM, and insulin as the first choice for pharmacologic therapy if needed 1, 2, 3, 4
Metformin can be considered only if the patient cannot safely or effectively use insulin, has no contraindications, and receives comprehensive counseling about placental transfer and long-term offspring concerns 2, 3, 4, 5

Do not continue metformin in women with polycystic ovary syndrome (PCOS) once pregnancy is confirmed unless there are specific indications like type 2 diabetes, as randomized trials show no benefit in preventing spontaneous abortion or GDM 1, 2, 4, 5
Do not use metformin for GDM prevention in high-risk women with obesity or PCOS, as meta-analyses show it does not reduce GDM risk 1
Do not assume metformin monotherapy will be sufficient - be prepared to add insulin in 25-46% of cases 1, 2, 3
Do not use metformin when placental insufficiency is suspected due to risks of growth restriction and acidosis 2, 3